393 related articles for article (PubMed ID: 28223167)
1. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
[TBL] [Abstract][Full Text] [Related]
2. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
3. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
[TBL] [Abstract][Full Text] [Related]
4. Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors.
Papa S; van Schalkwyk M; Maher J
Methods Mol Biol; 2015; 1317():365-82. PubMed ID: 26072418
[TBL] [Abstract][Full Text] [Related]
5. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.
Mayor M; Zeltsman M; McGee E; Adusumilli PS
Immunotherapy; 2016 May; 8(5):491-4. PubMed ID: 27140404
[No Abstract] [Full Text] [Related]
6. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
[No Abstract] [Full Text] [Related]
8. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
Zhao Y; Moon E; Carpenito C; Paulos CM; Liu X; Brennan AL; Chew A; Carroll RG; Scholler J; Levine BL; Albelda SM; June CH
Cancer Res; 2010 Nov; 70(22):9053-61. PubMed ID: 20926399
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
10. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
Beatty GL; Haas AR; Maus MV; Torigian DA; Soulen MC; Plesa G; Chew A; Zhao Y; Levine BL; Albelda SM; Kalos M; June CH
Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
[TBL] [Abstract][Full Text] [Related]
12. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
Moon EK; Carpenito C; Sun J; Wang LC; Kapoor V; Predina J; Powell DJ; Riley JL; June CH; Albelda SM
Clin Cancer Res; 2011 Jul; 17(14):4719-30. PubMed ID: 21610146
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
14. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
O'Hara MH; Stashwick C; Plesa G; Tanyi JL
Immunotherapy; 2017 Aug; 9(9):767-780. PubMed ID: 28771103
[TBL] [Abstract][Full Text] [Related]
15. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ
Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629
[TBL] [Abstract][Full Text] [Related]
16. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.
Li H; Huang Y; Jiang DQ; Cui LZ; He Z; Wang C; Zhang ZW; Zhu HL; Ding YM; Li LF; Li Q; Jin HJ; Qian QJ
Cell Death Dis; 2018 Feb; 9(2):177. PubMed ID: 29415996
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
19. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
20. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
Zeltsman M; Dozier J; McGee E; Ngai D; Adusumilli PS
Transl Res; 2017 Sep; 187():1-10. PubMed ID: 28502785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
